MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

Home・Akcijų sąrašas・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

33.82 1.5

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

33.32

Max

34.23

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-14M -81M
Pardavimai	75K 75K
Pelnas, tenkantis vienai akcijai	-1.22
Pelno marža	-108,422.667
Darbuotojai	198
EBITDA	-7.8M -81M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+63.52% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	472M 2.1B
Ankstesnė atidarymo kaina	32.32
Ankstesnė uždarymo kaina	33.82

Naujienos nuotaikos

By Acuity

100%

335 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

18.91 / 20.63 Palaikymas ir pasipriešinimas

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-14 23:36; UTC

Įsigijimai, susijungimai, perėmimai

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

2026-04-14 23:24; UTC

Karštos akcijos

Stocks to Watch: Gloo, Broadcom, GitLab

2026-04-14 22:42; UTC

Įsigijimai, susijungimai, perėmimai

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

2026-04-14 21:32; UTC

Pagrindinės rinkos jėgos

GitLab Shares Rise on Expanded Google Cloud Collaboration

2026-04-14 23:54; UTC

Rinkos pokalbiai

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

2026-04-14 23:34; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Technical Correction -- Market Talk

2026-04-14 22:54; UTC

Uždarbis

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

2026-04-14 22:54; UTC

Uždarbis

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

2026-04-14 22:54; UTC

Uždarbis

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

2026-04-14 22:54; UTC

Uždarbis

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

2026-04-14 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Targets Deal Completion Toward End of 3Q

2026-04-14 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

2026-04-14 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

2026-04-14 22:16; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

2026-04-14 22:15; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

2026-04-14 22:14; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

2026-04-14 22:13; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

2026-04-14 22:12; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

2026-04-14 22:12; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

2026-04-14 22:10; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

2026-04-14 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-04-14 20:33; UTC

Įsigijimai, susijungimai, perėmimai

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

2026-04-14 20:32; UTC

Karštos akcijos

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

2026-04-14 19:59; UTC

Įsigijimai, susijungimai, perėmimai

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

2026-04-14 19:38; UTC

Uždarbis

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

2026-04-14 19:27; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

2026-04-14 19:21; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

2026-04-14 19:09; UTC

Įsigijimai, susijungimai, perėmimai

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

2026-04-14 18:30; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-14 18:30; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

63.52% į viršų

12 mėnesių prognozė

Vidutinis 54.5 USD 63.52%

Aukščiausias 90 USD

Žemiausias 24 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Celldex Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.